Martin Hendrix

Head of Global Business Development and M&A, Nestlé Health Science

Martin joined NHSc in 2012 with the task of building a healthcare M&A capability for the group. Since then he has kept a relentless passion for growing the company’s portfolio through creative deals, ranging from large M&A transactions to small licensing deals and everything in between.

Martin has a background in pharmaceutical R&D. 

Prior to joining Nestlé he had a 14 year career at Bayer, starting out as a research chemist developing new medicines and later transitioning into M&A and corporate development. Martin likes the unique balance of NHSc’s approach to leverage the power of nutrition in both consumer health as well as medical nutrition and therapeutic products, with consumer deals like the acquisition of Atrium Innovations or the SpoonfulOne brand, and therapeutic deals like the acquisition of Zenpep, or innovation investments for topics such as food allergy, the human microbiome and metabolic health.

Martin is also a champion of NHSc’s venture investment strategy, which includes its partnership with Flagship Pioneering, as well as multiple direct investments in start-up companies. In connection with these investments, he has represented NHSc in the boards of Enterome, Microbiome Diagnostic Partners, Evelo, Kaleido, and Kintai.

Martin holds a Ph.D. from The Scripps Research Institute, and a Master of Science from the Georgia Institute of Technology.